Treatment | Page 374 of 465

Psychiatry :: UCLA Faculty Recognized for Outstanding Achievement in Psychiatric Research

Three UCLA scientists will be awarded top prizes for psychiatric research on Friday by NARSAD: The Mental Health Research Association, the world’s largest donor-supported organization dedicated to funding innovative research on severe mental illnesses. Lori Altshuler, M.D.; Joaquin M. Fuster, M.D., Ph.D., and Tyrone D. Cannon, Ph.D., all of UCLA’s Semel Institute, will be presented their awards at NARSAD’s 19th annual ceremony in New York City.

Candidiasis :: Schering-Plough’s NOXAFIL, Posaconazole for Treatment of Oropharyngeal Candidiasis OPC

Schering-Plough Corporation (NYSE: SGP) reported that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL(R) (posaconazole) Oral Suspension for the treatment of oropharyngeal candidiasis (OPC), including infections refractory to itraconazole and/or fluconazole. OPC is a fungal infection of the mouth and throat caused by the yeast Candida. NOXAFIL is a novel triazole antifungal agent discovered and developed by Schering-Plough Research Institute.

Constipation :: Unfounded fear of addiction prevents laxative use

Many people with constipation are confused about the cause of their condition and its appropriate treatment with laxatives. Results of a new large-scale global survey, announced today, show that many people wrongly fear that laxatives are addictive and that their use for long periods of time actually causes constipation.1,2

Ulcerative Colitis :: Mesalamine associated with rapid mucosal healing in ulcerative colitis patients

Combined data analysis from two trials demonstrated that treatment success is associated with mucosal healing in patients with moderately active ulcerative colitis who received either 2.4 or 4.8 grams of mesalamine per day. By 6 weeks, 67% of patients achieved both treatment success and mucosal healing, while only 5% achieved treatment success without demonstrating mucosal healing. The results were presented by University of Chicago researcher David T. Rubin, MD, at the annual scientific meeting of the American College of Gastroenterology (ACG).

Ulcerative Colitis :: Adherence to ulcerative colitis medications is not affected by drug formulation or dosing regimen

Poor adherence to medication is a recognized medical problem, costing an estimated $100 billion a year in the United States.(i) New data show that while there is a steady decline in adherence to medications for ulcerative colitis (UC), drug formulation and the number of pills taken each day do not affect long-term adherence. The data were presented today at the annual scientific meeting of the American College of Gastroenterology by University of Chicago researcher Sunanda Kane, M.D.

Herpes :: Merck’s shingles vaccine Zostavax, Zoster Vaccine Live for herpes zoster

Merck & Co., Inc. announced that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) voted unanimously to recommend that adults 60 years of age and older be vaccinated with ZOSTAVAX? [Zoster Vaccine Live (Oka/Merck)] to help prevent shingles (herpes zoster), a frequently painful disease marked by a blistering rash.

Dyspepsia :: Zelnorm, tegaserod maleate for relief of multiple symptoms of dyspepsia – Novartis

The gastrointestinal medicine Zelnorm? (tegaserod maleate) has demonstrated potential benefits in helping patients with the multiple symptoms of a common digestive disorder called dysmotility-type dyspepsia[1], according to new Phase III data presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting.

Hepatitis :: Tyzeka, Sebivo or telbivudine for patients with chronic hepatitis B – Novartis

Novartis announced the US regulatory approval of Tyzeka(TM) (telbivudine) as a new once-a-day oral treatment for patients with chronic hepatitis B, a disease estimated to affect about 1.25 million people in the US but more than 350 million globally and considered the tenth leading cause of death.

Tooth Decay :: New Weapon in Fight Against Tooth Decay

A group of scientists representing the UCLA School of Dentistry; the UCLA Department of Microbiology, Immunology and Molecular Genetics, and C3 Jian Corporation have succeeded in creating a pheromone-guided “smart” anti-microbial peptide capable of selectively eliminating Streptococcus mutans, a leading bacterial cause of tooth decay, in 30 seconds.

HIV :: Most HIV infected individuals with inadequate outpatient medical care

In a first-of-its-kind study, UCLA researchers have shown that segments of the HIV-infected population who have little to no consistent outpatient medical care ? and yet are most in need of such services ? are overwhelmingly minorities, the poor and substance abusers.